In Sight : : My Life in Science and Health Innovation / / Julia Levy.

• Superior document: Title is part of eBook package: De Gruyter ACUP Complete eBook-Package 2020
• VerfasserIn: Levy, Julia,
• MitwirkendeR: Shoichet, Molly,
• Place / Publishing House: Toronto : : University of Toronto Press, , [2020]; ©2020
• Year of Publication: 2020
• Language: English
• Physical Description: 1 online resource (312 p.) :; 15 b&w illustrations

In Sight is a memoir about how a love of science and discovery drove Julia Levy, a celebrated scholar and biotech CEO, to work her way through gender bias in order to achieve academic and professional recognition. Her story traces the unconventional invention of a breakthrough drug treatment from its development from laboratory research to its application as a medical treatment for vision loss. Told from a female perspective, In Sight is a unique and personal story covering Levy’s early years as a refugee, her university training in the UK, and her appointment as professor at the University of British Columbia. Years spent as an academic led the author to unexpected exposure to the biotechnology industry and a chance meeting with colleagues that led to the formation of a lucrative biotechnology company, known today as QLT Inc. The bulk of the book covers the years spent building the company, and Levy’s surprising transition from chief scientific officer to CEO. In Sight is an honest description of the trials of drug development, the tensions inherent in the commercialization of health innovations, and the truly remarkable hurdles faced by women in the scientific community.

Table of Contents

Frontmatter -- Contents -- Foreword -- 1 Waiting for the Other Shoe to Drop -- 2 Does Your Dog Always Sit in the Front Seat? -- 3 Where I Wanted to Be -- 4 Life in Bed-Sits -- 5 Woefully Outclassed -- 6 Whose Lab Do You Work in? -- 7 Earning My Stripes -- 8 Seeing the Light -- 9 Becoming Part of a Biotech Start-Up -- 10 Positioning QLT as a Photodynamic Therapy Company -- 11 Colleagues at American Cyanamid Come to Our Rescue -- 12 The Nation’s Blood Supply -- 13 PDT Is Different from Other Cancer Drugs -- 14 I Was Surprised and Not at All Pleased -- 15 Splitting Up -- 16 Failure Was Never an Option -- 17 Nothing Can Prepare You for the Torture of ODAC -- 18 Taking Big Steps in Our AMD Clinical Trials -- 19 An Open and Respectful Relationship -- 20 Our Work on Age-Related Macular Degeneration Is Her Legacy -- 21 We at QLT Were on Pins and Needles -- 22 People Couldn’t Stop Smiling -- 23 More Than a One-Trick Pony -- 24 Launching the Product and Hoping for No Unpleasant Surprises -- 25 Growing the Company -- 26 Time to Reflect -- 27 An Enormous Rush of Relief -- 28 A Biotech Company with a Lot of Money Is in Danger -- 29 I Thought These Problems Would Be Transient -- 30 Ongoing Headaches -- 31 He Felt Thoroughly Betrayed -- 32 Problems with Activist Shareholders -- 33 New Opportunity -- Acknowledgments -- About the Author -- Index